Summary

The global Biologics for Obstructive Airway Diseases market is projected to grow from US$ 9317 million in 2025 to US$ 16224 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Biologics for Obstructive Airway Diseases refer to biologic medicines produced using biotechnology that exert therapeutic effects by specifically modulating targets or signaling pathways associated with airway inflammation, allergic responses, and immune reactions, and that are classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines primarily act by targeting key inflammatory mediators or receptors, including immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin, thereby reducing airway inflammation, eosinophil activation, and allergic responses. They are mainly used to reduce disease exacerbations, improve lung function, and enhance disease control in severe asthma, chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications.
For the purposes of this report, a product is included only when it meets both criteria: it is classified under ATC R03 and it qualifies as a biologic medicine. Inhaled corticosteroids, bronchodilators, leukotriene receptor antagonists, and other small-molecule medicines within R03 are excluded. Biologic medicines outside R03 are also excluded even if they are used to treat asthma, chronic obstructive pulmonary disease, or other respiratory diseases. Both originator biologics and biosimilars are included under their corresponding active substances and ATC classifications.
Biologics for obstructive airway diseases are biologic medicines produced using biotechnology and classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines act primarily by specifically targeting key molecules involved in airway inflammation, allergic responses, and immune regulation. Current major targets include immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin. They are mainly used for severe asthma, selected forms of chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications. The industry excludes inhaled corticosteroids, bronchodilators, and other small-molecule drugs within R03, as well as respiratory biologics whose ATC classifications fall outside R03.
By product structure, monoclonal antibodies account for the dominant share of biologics for obstructive airway diseases. Representative active substances include omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, and depemokimab. These products achieve differentiated therapeutic effects by inhibiting immunoglobulin E, eosinophil-related pathways, or upstream inflammatory mediators. Immunoglobulin E-targeted therapies have been commercialized for a relatively long period and are entering a market environment in which originator products and biosimilars coexist. Interleukin-5 and interleukin-5 receptor therapies primarily target severe eosinophilic asthma, while thymic stromal lymphopoietin-targeted therapies act further upstream in the inflammatory cascade and may therefore cover a broader patient population.
By therapeutic application, severe asthma currently represents the principal area of use. Biologics are generally used in patients whose disease remains inadequately controlled with conventional inhaled therapies and who exhibit identifiable allergic, eosinophilic, or other inflammatory phenotypes. As biomarker testing and patient stratification improve, clinical management is shifting from conventional symptom control toward precision treatment based on disease phenotype and underlying inflammatory mechanisms. At the same time, selected biologics are expanding into chronic obstructive pulmonary disease, particularly among patients with eosinophilic inflammation, creating an additional source of industry growth.
Subcutaneous injection is currently the dominant route of administration. Several products are available in prefilled syringes or autoinjectors, allowing treatment to gradually shift from hospitals and specialty clinics toward homecare settings. A limited number of products continue to be administered by intravenous infusion, primarily in hospitals or specialized healthcare facilities. Longer dosing intervals, more convenient delivery devices, and improved self-administration capabilities are becoming important competitive attributes for next-generation therapies, helping improve long-term adherence and reduce the treatment burden on patients.
The upstream supply chain primarily includes cell lines, culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins, buffer materials, syringes, and other sterile packaging components. Midstream activities include cell culture, harvest, purification, viral clearance, drug substance preparation, formulation, aseptic filling, quality testing, and batch release. Downstream access is primarily through hospitals, respiratory and allergy specialty clinics, specialty pharmacies, and homecare settings. Because these products require stringent control of protein structure, purity, biological activity, aggregation, impurities, and sterility, manufacturing is subject to demanding quality management and batch consistency requirements.
From a manufacturing perspective, most products are produced using mammalian cell expression systems. Commercial manufacturing generally involves cell culture in bioreactors followed by multi-stage filtration and chromatography purification. Individual bioreactors in commercial production lines commonly range from approximately 2,000 to 20,000 liters, while large manufacturing facilities typically operate multiple bioreactors together with associated downstream purification systems. There is no single standardized annual capacity per production line, as effective output depends on antibody titer, culture cycle, batch frequency, bioreactor configuration, purification yield, and facility utilization. Large stainless-steel systems provide significant economies of scale for mature high-volume antibody products, whereas single-use systems offer greater flexibility for multiproduct and smaller-batch manufacturing.
Major cost components include culture media and single-use consumables, chromatography resins, facility depreciation, labor, quality testing, utilities, fill-finish operations, packaging, and cold-chain logistics. Unit manufacturing costs can decline materially as production scale and antibody titers increase, giving mature commercial products substantial economies of scale. Innovative originator biologics typically benefit from premium pricing and strong patent protection, and gross margins for mature products can generally reach approximately 60% to 85%. Biosimilars typically generate lower gross margins because of stronger price competition and distribution costs, although manufacturers with efficient large-scale production can still maintain attractive profitability.
The industry is characterized by high research and development, manufacturing, and regulatory barriers. Companies must not only complete complex clinical development and indication-specific validation but also establish biologics manufacturing systems that comply with good manufacturing practice requirements and consistently maintain product quality, aseptic control, and pharmacovigilance standards. For biosimilars, manufacturers must demonstrate a high degree of structural and functional similarity to the reference product and satisfy regulatory requirements concerning quality, clinical comparability, and immunogenicity. Companies with established cell culture, purification, and analytical quality platforms therefore possess significant competitive advantages.
The global competitive landscape remains relatively concentrated, with major originator products controlled by a limited number of large multinational pharmaceutical companies. These companies maintain their positions through extensive clinical evidence, indication expansion, brand recognition, and global commercialization networks. As patents for earlier products expire, mature molecules such as omalizumab are entering biosimilar competition, while biologics manufacturers from South Korea, China, and other regions are increasingly participating in the market. In China, the market remains in a stage of domestic substitution and increasing biologic penetration, with local companies initially targeting mature molecules such as omalizumab while expanding large-scale antibody manufacturing and commercialization capabilities.
Distribution and end-use patterns are highly specialized. Patients are commonly selected using serum immunoglobulin E levels, peripheral blood eosinophil counts, allergen testing, and other clinical indicators, making product use highly dependent on respiratory specialists, allergists, and other specialized physicians. As prefilled formulations, self-injection products, and remote patient-management models become more widely adopted, the proportion of home-based treatment is expected to increase. However, initial administration, response assessment, and monitoring for serious adverse events are expected to remain concentrated in professional healthcare settings.
Future industry growth will be driven primarily by higher penetration of biologic therapies in severe asthma, expansion into chronic obstructive pulmonary disease, development of novel inflammatory targets, biomarker-driven precision patient stratification, and improved patient access in emerging markets. At the same time, biosimilar competition for mature products such as omalizumab will continue to exert downward pressure on pricing, gradually shifting market growth from price-driven expansion toward growth in treated patient populations and new indications. Competition is therefore expected to move beyond efficacy at a single target toward a broader combination of patient coverage, lower dosing frequency, more convenient administration, long-term safety, and overall cost effectiveness.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Biologics for Obstructive Airway Diseases market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Novartis AG
Roche Group
GSK
AstraZeneca
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Celltrion, Inc.
Taizhou Mabtech Pharmaceutical Co., Ltd.
CSPC Megalith Biopharmaceutical Co., Ltd.
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
Segment by Type
gE Targeting
IL-5 Targeting
IL-5 Receptor Targeting
TSLP Targeting
Other Targets
Segment by Therapeutic Application
Asthma
Chronic Obstructive Pulmonary Disease
Other Obstructive Airway Diseases
Segment by Product Status
Originator Biologics
Biosimilars
Segment by Application
Hospitals
Specialty Clinics
Homecare Settings
Other Healthcare Settings
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Biologics for Obstructive Airway Diseases study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Biologics for Obstructive Airway Diseases: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Biologics for Obstructive Airway Diseases Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 gE Targeting
1.2.3 IL-5 Targeting
1.2.4 IL-5 Receptor Targeting
1.2.5 TSLP Targeting
1.2.6 Other Targets
1.3 Market Segmentation by Therapeutic Application
1.3.1 Global Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application, 2021 vs 2025 vs 2032
1.3.2 Asthma
1.3.3 Chronic Obstructive Pulmonary Disease
1.3.4 Other Obstructive Airway Diseases
1.4 Market Segmentation by Product Status
1.4.1 Global Biologics for Obstructive Airway Diseases Market Size by Product Status, 2021 vs 2025 vs 2032
1.4.2 Originator Biologics
1.4.3 Biosimilars
1.5 Market Segmentation by Application
1.5.1 Global Biologics for Obstructive Airway Diseases Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.5.4 Homecare Settings
1.5.5 Other Healthcare Settings
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Biologics for Obstructive Airway Diseases Revenue Estimates and Forecasts (2021-2032)
2.2 Global Biologics for Obstructive Airway Diseases Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Biologics for Obstructive Airway Diseases Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Biologics for Obstructive Airway Diseases Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 gE Targeting: Market Share by Key Players
3.3.2 IL-5 Targeting: Market Share by Key Players
3.3.3 IL-5 Receptor Targeting: Market Share by Key Players
3.3.4 TSLP Targeting: Market Share by Key Players
3.3.5 Other Targets: Market Share by Key Players
3.4 Global Biologics for Obstructive Airway Diseases Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Biologics for Obstructive Airway Diseases Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Biologics for Obstructive Airway Diseases Market by Therapeutic Application
4.2.1 Global Revenue by Therapeutic Application (2021-2032)
4.2.2 Global Revenue-Based Market Share by Therapeutic Application (2021-2032)
4.3 Global Biologics for Obstructive Airway Diseases Market by Product Status
4.3.1 Global Revenue by Product Status (2021-2032)
4.3.2 Global Revenue-Based Market Share by Product Status (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Biologics for Obstructive Airway Diseases Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Biologics for Obstructive Airway Diseases Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Biologics for Obstructive Airway Diseases Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Biologics for Obstructive Airway Diseases Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Biologics for Obstructive Airway Diseases Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Biologics for Obstructive Airway Diseases Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Novartis AG
11.1.1 Novartis AG Corporation Information
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Biologics for Obstructive Airway Diseases Product Features and Attributes
11.1.4 Novartis AG Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.1.5 Novartis AG Biologics for Obstructive Airway Diseases Revenue by Product in 2025
11.1.6 Novartis AG Biologics for Obstructive Airway Diseases Revenue by Application in 2025
11.1.7 Novartis AG Biologics for Obstructive Airway Diseases Revenue by Geographic Area in 2025
11.1.8 Novartis AG Biologics for Obstructive Airway Diseases SWOT Analysis
11.1.9 Novartis AG Recent Developments
11.2 Roche Group
11.2.1 Roche Group Corporation Information
11.2.2 Roche Group Business Overview
11.2.3 Roche Group Biologics for Obstructive Airway Diseases Product Features and Attributes
11.2.4 Roche Group Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.2.5 Roche Group Biologics for Obstructive Airway Diseases Revenue by Product in 2025
11.2.6 Roche Group Biologics for Obstructive Airway Diseases Revenue by Application in 2025
11.2.7 Roche Group Biologics for Obstructive Airway Diseases Revenue by Geographic Area in 2025
11.2.8 Roche Group Biologics for Obstructive Airway Diseases SWOT Analysis
11.2.9 Roche Group Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Business Overview
11.3.3 GSK Biologics for Obstructive Airway Diseases Product Features and Attributes
11.3.4 GSK Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.3.5 GSK Biologics for Obstructive Airway Diseases Revenue by Product in 2025
11.3.6 GSK Biologics for Obstructive Airway Diseases Revenue by Application in 2025
11.3.7 GSK Biologics for Obstructive Airway Diseases Revenue by Geographic Area in 2025
11.3.8 GSK Biologics for Obstructive Airway Diseases SWOT Analysis
11.3.9 GSK Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Biologics for Obstructive Airway Diseases Product Features and Attributes
11.4.4 AstraZeneca Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.4.5 AstraZeneca Biologics for Obstructive Airway Diseases Revenue by Product in 2025
11.4.6 AstraZeneca Biologics for Obstructive Airway Diseases Revenue by Application in 2025
11.4.7 AstraZeneca Biologics for Obstructive Airway Diseases Revenue by Geographic Area in 2025
11.4.8 AstraZeneca Biologics for Obstructive Airway Diseases SWOT Analysis
11.4.9 AstraZeneca Recent Developments
11.5 Amgen Inc.
11.5.1 Amgen Inc. Corporation Information
11.5.2 Amgen Inc. Business Overview
11.5.3 Amgen Inc. Biologics for Obstructive Airway Diseases Product Features and Attributes
11.5.4 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.5.5 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue by Product in 2025
11.5.6 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue by Application in 2025
11.5.7 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue by Geographic Area in 2025
11.5.8 Amgen Inc. Biologics for Obstructive Airway Diseases SWOT Analysis
11.5.9 Amgen Inc. Recent Developments
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Teva Pharmaceutical Industries Ltd. Corporation Information
11.6.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.6.3 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product Features and Attributes
11.6.4 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.6.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.7 Celltrion, Inc.
11.7.1 Celltrion, Inc. Corporation Information
11.7.2 Celltrion, Inc. Business Overview
11.7.3 Celltrion, Inc. Biologics for Obstructive Airway Diseases Product Features and Attributes
11.7.4 Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.7.5 Celltrion, Inc. Recent Developments
11.8 Taizhou Mabtech Pharmaceutical Co., Ltd.
11.8.1 Taizhou Mabtech Pharmaceutical Co., Ltd. Corporation Information
11.8.2 Taizhou Mabtech Pharmaceutical Co., Ltd. Business Overview
11.8.3 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product Features and Attributes
11.8.4 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.8.5 Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments
11.9 CSPC Megalith Biopharmaceutical Co., Ltd.
11.9.1 CSPC Megalith Biopharmaceutical Co., Ltd. Corporation Information
11.9.2 CSPC Megalith Biopharmaceutical Co., Ltd. Business Overview
11.9.3 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product Features and Attributes
11.9.4 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.9.5 CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments
11.10 Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
11.10.1 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Corporation Information
11.10.2 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Business Overview
11.10.3 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product Features and Attributes
11.10.4 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments

12 Biologics for Obstructive Airway Diseases Value Chain and Ecosystem Analysis
12.1 Biologics for Obstructive Airway Diseases Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Biologics for Obstructive Airway Diseases Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Biologics for Obstructive Airway Diseases Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Therapeutic Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Product Status, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Biologics for Obstructive Airway Diseases Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Biologics for Obstructive Airway Diseases Revenue by Region (US$ Million), 2021-2026
Table 7. Global Biologics for Obstructive Airway Diseases Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Biologics for Obstructive Airway Diseases Revenue by Players (US$ Million), 2021-2026
Table 10. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Biologics for Obstructive Airway Diseases Revenue, 2025
Table 13. Global Biologics for Obstructive Airway Diseases Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Biologics for Obstructive Airway Diseases Companies Headquarters
Table 15. Global Biologics for Obstructive Airway Diseases Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Biologics for Obstructive Airway Diseases Revenue by Type (US$ Million), 2021-2026
Table 19. Global Biologics for Obstructive Airway Diseases Revenue by Type (US$ Million), 2027-2032
Table 20. Global Biologics for Obstructive Airway Diseases Revenue by Therapeutic Application (US$ Million), 2021-2026
Table 21. Global Biologics for Obstructive Airway Diseases Revenue by Therapeutic Application (US$ Million), 2027-2032
Table 22. Global Biologics for Obstructive Airway Diseases Revenue by Product Status (US$ Million), 2021-2026
Table 23. Global Biologics for Obstructive Airway Diseases Revenue by Product Status (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Biologics for Obstructive Airway Diseases Revenue by Application (US$ Million), 2021-2026
Table 26. Global Biologics for Obstructive Airway Diseases Revenue by Application (US$ Million), 2027-2032
Table 27. Biologics for Obstructive Airway Diseases High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Biologics for Obstructive Airway Diseases Growth Accelerators and Market Barriers
Table 31. North America Biologics for Obstructive Airway Diseases Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Biologics for Obstructive Airway Diseases Growth Accelerators and Market Barriers
Table 33. Europe Biologics for Obstructive Airway Diseases Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Biologics for Obstructive Airway Diseases Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Biologics for Obstructive Airway Diseases Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Biologics for Obstructive Airway Diseases Investment Opportunities and Key Challenges
Table 37. Central and South America Biologics for Obstructive Airway Diseases Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Biologics for Obstructive Airway Diseases Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Biologics for Obstructive Airway Diseases Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Novartis AG Corporation Information
Table 41. Novartis AG Description and Major Businesses
Table 42. Novartis AG Product Features and Attributes
Table 43. Novartis AG Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Novartis AG Revenue Proportion by Product in 2025
Table 45. Novartis AG Revenue Proportion by Application in 2025
Table 46. Novartis AG Revenue Proportion by Geographic Area in 2025
Table 47. Novartis AG Biologics for Obstructive Airway Diseases SWOT Analysis
Table 48. Novartis AG Recent Developments
Table 49. Roche Group Corporation Information
Table 50. Roche Group Description and Major Businesses
Table 51. Roche Group Product Features and Attributes
Table 52. Roche Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Roche Group Revenue Proportion by Product in 2025
Table 54. Roche Group Revenue Proportion by Application in 2025
Table 55. Roche Group Revenue Proportion by Geographic Area in 2025
Table 56. Roche Group Biologics for Obstructive Airway Diseases SWOT Analysis
Table 57. Roche Group Recent Developments
Table 58. GSK Corporation Information
Table 59. GSK Description and Major Businesses
Table 60. GSK Product Features and Attributes
Table 61. GSK Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. GSK Revenue Proportion by Product in 2025
Table 63. GSK Revenue Proportion by Application in 2025
Table 64. GSK Revenue Proportion by Geographic Area in 2025
Table 65. GSK Biologics for Obstructive Airway Diseases SWOT Analysis
Table 66. GSK Recent Developments
Table 67. AstraZeneca Corporation Information
Table 68. AstraZeneca Description and Major Businesses
Table 69. AstraZeneca Product Features and Attributes
Table 70. AstraZeneca Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. AstraZeneca Revenue Proportion by Product in 2025
Table 72. AstraZeneca Revenue Proportion by Application in 2025
Table 73. AstraZeneca Revenue Proportion by Geographic Area in 2025
Table 74. AstraZeneca Biologics for Obstructive Airway Diseases SWOT Analysis
Table 75. AstraZeneca Recent Developments
Table 76. Amgen Inc. Corporation Information
Table 77. Amgen Inc. Description and Major Businesses
Table 78. Amgen Inc. Product Features and Attributes
Table 79. Amgen Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Amgen Inc. Revenue Proportion by Product in 2025
Table 81. Amgen Inc. Revenue Proportion by Application in 2025
Table 82. Amgen Inc. Revenue Proportion by Geographic Area in 2025
Table 83. Amgen Inc. Biologics for Obstructive Airway Diseases SWOT Analysis
Table 84. Amgen Inc. Recent Developments
Table 85. Teva Pharmaceutical Industries Ltd. Corporation Information
Table 86. Teva Pharmaceutical Industries Ltd. Description and Major Businesses
Table 87. Teva Pharmaceutical Industries Ltd. Product Features and Attributes
Table 88. Teva Pharmaceutical Industries Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 90. Celltrion, Inc. Corporation Information
Table 91. Celltrion, Inc. Description and Major Businesses
Table 92. Celltrion, Inc. Product Features and Attributes
Table 93. Celltrion, Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Celltrion, Inc. Recent Developments
Table 95. Taizhou Mabtech Pharmaceutical Co., Ltd. Corporation Information
Table 96. Taizhou Mabtech Pharmaceutical Co., Ltd. Description and Major Businesses
Table 97. Taizhou Mabtech Pharmaceutical Co., Ltd. Product Features and Attributes
Table 98. Taizhou Mabtech Pharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments
Table 100. CSPC Megalith Biopharmaceutical Co., Ltd. Corporation Information
Table 101. CSPC Megalith Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 102. CSPC Megalith Biopharmaceutical Co., Ltd. Product Features and Attributes
Table 103. CSPC Megalith Biopharmaceutical Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments
Table 105. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Corporation Information
Table 106. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Description and Major Businesses
Table 107. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Product Features and Attributes
Table 108. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments
Table 110. Technologies, Platforms and Infrastructure
Table 111. Distributors List
Table 112. Market Trends and Market Evolution
Table 113. Market Drivers and Opportunities
Table 114. Market Challenges, Risks, and Restraints
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. gE Targeting Product Picture
Figure 3. IL-5 Targeting Product Picture
Figure 4. IL-5 Receptor Targeting Product Picture
Figure 5. TSLP Targeting Product Picture
Figure 6. Other Targets Product Picture
Figure 7. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Therapeutic Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Asthma Product Picture
Figure 9. Chronic Obstructive Pulmonary Disease Product Picture
Figure 10. Other Obstructive Airway Diseases Product Picture
Figure 11. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Product Status, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Originator Biologics Product Picture
Figure 13. Biosimilars Product Picture
Figure 14. Global Biologics for Obstructive Airway Diseases Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Hospitals
Figure 16. Specialty Clinics
Figure 17. Homecare Settings
Figure 18. Other Healthcare Settings
Figure 19. Biologics for Obstructive Airway Diseases Report Years Considered
Figure 20. Global Biologics for Obstructive Airway Diseases Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 22. Global Biologics for Obstructive Airway Diseases Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. gE Targeting Revenue-Based Market Share by Player in 2025
Figure 27. IL-5 Targeting Revenue-Based Market Share by Player in 2025
Figure 28. IL-5 Receptor Targeting Revenue-Based Market Share by Player in 2025
Figure 29. TSLP Targeting Revenue-Based Market Share by Player in 2025
Figure 30. Other Targets Revenue-Based Market Share by Player in 2025
Figure 31. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share by Therapeutic Application (2021-2032)
Figure 33. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share by Product Status (2021-2032)
Figure 34. Global Biologics for Obstructive Airway Diseases Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Biologics for Obstructive Airway Diseases Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Biologics for Obstructive Airway Diseases Revenue (US$ Million) in 2025
Figure 37. North America Biologics for Obstructive Airway Diseases Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 39. Canada Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 40. Mexico Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 41. Europe Biologics for Obstructive Airway Diseases Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Biologics for Obstructive Airway Diseases Revenue (US$ Million) in 2025
Figure 43. Europe Biologics for Obstructive Airway Diseases Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 45. France Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 46. U.K. Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 47. Italy Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 48. Russia Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Biologics for Obstructive Airway Diseases Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Biologics for Obstructive Airway Diseases Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Biologics for Obstructive Airway Diseases Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 53. Japan Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 54. South Korea Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 55. Australia Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 56. India Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 60. Philippines Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 61. Singapore Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Biologics for Obstructive Airway Diseases Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Biologics for Obstructive Airway Diseases Revenue (US$ Million) in 2025
Figure 64. Central and South America Biologics for Obstructive Airway Diseases Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 66. Argentina Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Biologics for Obstructive Airway Diseases Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Biologics for Obstructive Airway Diseases Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Biologics for Obstructive Airway Diseases Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 71. Israel Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 72. Egypt Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 73. South Africa Biologics for Obstructive Airway Diseases Revenue (US$ Million), 2021-2032
Figure 74. Biologics for Obstructive Airway Diseases Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed